Penny stocks can be a very real gamble.

‍

But when those gambles pay off, the rewards are significant.

‍

Such is the case today with Tenaya Therapeutics (NASDAQ: TNYA), which just locked in a new research collaboration with Alnylam Pharmaceuticals (NASDAQ: ALNY) to identify and validate novel genetic targets for cardiovascular therapies.

‍

Here’s how the market reacted to the news …

‍

‍

This partnership essentially ushers Tenaya into the world of top-tier biotech players, with Alnylam (boasting a market cap of $42.5 billion) being the escort. For a tiny stock like Tenaya, this isn’t trivial.

‍

Targeting the Genetics of Heart Disease

‍

Tenaya Therapeutics has built its business around the thesis that many forms of heart disease can be treated at their genetic roots.
‍

The company focuses on developing therapies for inherited cardiovascular disorders through platforms that include gene therapy, cellular regeneration, and precision medicine. Its existing pipeline includes experimental therapies targeting conditions such as hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, and other genetically driven heart disorders.

‍

But this new collaboration aims to push things even further.  

‍

With the Alnylam partnership in place, the goal now is to identify up to 15 new genetic targets that could lead to entirely new cardiovascular treatments.

‍

In other words, instead of just developing therapies for known mutations, the partnership could help uncover the next generation of genetic drivers of heart disease. 

‍

To be sure, Alnylam Pharmaceuticals isn’t just another biotech partner.

‍

The company is a pioneer in RNA interference (RNAi) therapeutics, a technology designed to silence disease-causing genes. By partnering with Tenaya, the two companies can combine complementary strengths: Tenaya’s expertise in cardiovascular genetics and gene therapy, and Alnylam’s experience in RNA-based drug development.

‍
Together, the two companies will work to discover new targets that could potentially be addressed using RNA-based medicines. And if successful, those targets could become the foundation for entirely new cardiovascular therapies.

‍

It’s also worth noting that this partnership reflects a larger shift happening across the biotech industry.

‍

For decades, cardiovascular disease has largely been treated with drugs that manage symptoms, such as lowering cholesterol, controlling blood pressure, or preventing clotting.

‍

But advances in genetics are opening a different path.

‍

Instead of managing disease, scientists are increasingly trying to correct or silence the genetic drivers that cause it. That’s the promise behind gene therapy and RNA-based medicine. And companies like Tenaya are trying to bring that approach to heart disease.

‍

Indeed, investing in microcaps like Tenaya Therapeutics can be quite risky.  But they can also pay off quite well if you know how to time them.  Certainly, this was the case for Tenaya today.

‍

‍